NEW YORK (GenomeWeb News) – Biocartis and BioMérieux on Thursday announced a mutual agreement to end their alliance to develop and commercialize the integrated molecular biology system called Idylla.

All rights to the platform, formerly called Apollo and developed by Biocartis in collaboration with Philips Corporate Technologies, will be returned to Biocartis, which will have all rights to Idylla now related to its use in the microbiology field, Biocartis said. The company also is free to explore new strategic options for the platform in the microbiology field, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.